IBB - ETF AI Analysis
Top Page
iShares Biotechnology ETF (IBB)
Rating:66Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and over recent months, showing positive momentum for investors.
Leading Biotech Companies at the Top
Several of the largest holdings, including well-known biotech leaders, have shown steady to strong performance, helping support the fund’s returns.
Healthy Fund Size
The ETF manages a large pool of assets, which can help with trading liquidity and reduce the risk of the fund being closed.
Negative Factors
Sector Concentration in Health Care
Almost all of the fund is invested in health care and biotechnology, which increases the risk if this single sector faces a downturn.
Heavy U.S. Focus
The ETF is almost entirely invested in U.S. companies, offering little geographic diversification if the U.S. market or regulatory environment weakens.
Mixed Performance Among Top Holdings
While some major positions have done well, a few key holdings have shown weak or negative performance, which can create more ups and downs for the fund.
IBB vs. SPDR S&P 500 ETF (SPY)
AUM10.47B
RegionNorth America
Expense Ratio0.44%
Beta0.76
IssueriShares
Inception DateFeb 05, 2001
Dividend Yield0.2%
Asset ClassEquity
Index TrackedNYSE Biotechnology (TR)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,728,018
30 Day Avg. Volume1,591,045
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
255.51Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering237
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBB Summary
The iShares Biotechnology ETF (IBB) is a fund that follows the NYSE Biotechnology Index, giving you a simple way to invest in many U.S. biotech companies at once. It holds well-known names like Amgen and Gilead Sciences, along with smaller firms working on new drugs, genetic tests, and other medical breakthroughs. Someone might invest in IBB for growth potential and to diversify within the health care sector, instead of trying to pick individual biotech stocks. However, biotech shares can be very volatile, so the ETF’s price can swing sharply and may go up or down quickly with news about drug approvals or failures.
How much will it cost me?The iShares Biotechnology ETF (IBB) has an expense ratio of 0.44%, which means you’ll pay $4.40 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to track the biotechnology industry. It’s a reasonable cost for the specialized exposure it provides.
What would affect this ETF?The iShares Biotechnology ETF (IBB) could benefit from advancements in medical research, increased demand for innovative treatments, and supportive government policies for health care innovation. However, it may face challenges from regulatory hurdles, high development costs, and potential market volatility tied to interest rate changes or broader economic conditions. Its focus on U.S.-listed biotechnology companies means it is heavily influenced by trends in the U.S. health care sector and the performance of top holdings like Gilead Sciences and Vertex Pharmaceuticals.
IBB Top 10 Holdings
IBB is very much a U.S. biotech story, with a heavy tilt toward a handful of big drug developers that set the tone for the fund. Amgen, Vertex, and Gilead are all rising steadily, acting as the fund’s anchor and providing a smoother ride in an otherwise volatile space. Regeneron and Argenx are also climbing, adding extra lift. On the more dramatic side, Moderna is surging on renewed momentum but remains a bit of a roller coaster, while Illumina’s rebound helps offset earlier stumbles. Overall, performance is driven by a concentrated group of innovative, large-cap biotechs.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Amgen | 8.53% | $897.18M | $233.78B | 50.30% | 77 Outperform | |
| Vertex Pharmaceuticals | 8.04% | $845.76M | $137.30B | 38.53% | 78 Outperform | |
| Gilead Sciences | 7.20% | $757.25M | $180.64B | 28.95% | 78 Outperform | |
| Regeneron | 5.70% | $599.80M | $81.77B | 36.76% | 78 Outperform | |
| Argenx Se | 3.78% | $397.88M | $64.89B | 43.67% | 79 Outperform | |
| Moderna | 3.57% | $375.24M | $55.09B | 472.81% | 59 Neutral | |
| Natera | 3.17% | $333.46M | $47.03B | 93.91% | 73 Outperform | |
| Revolution Medicines | 2.82% | $296.21M | $44.56B | 447.48% | 52 Neutral | |
| Illumina | 2.31% | $243.49M | $32.55B | 115.68% | 71 Outperform | |
| Biogen | 2.27% | $239.35M | $32.28B | 65.25% | 74 Outperform |
IBB Technical Analysis
Positive
―
Price Trends
195.28
Positive
182.83
Positive
176.48
Positive
Market Momentum
5.93
Positive
58.89
Neutral
54.54
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBB, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 204.71, equal to the 50-day MA of 195.28, and equal to the 200-day MA of 176.48, indicating a bullish trend. The MACD of 5.93 indicates Positive momentum. The RSI at 58.89 is Neutral, neither overbought nor oversold. The STOCH value of 54.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBB.
IBB Peer Comparison
Comparison Results
Performance Comparison
IBB
iShares Biotechnology ETF
210.82
70.77
50.53%
VGT
Vanguard Information Technology ETF
―
―
―
XLK
Technology Select Sector SPDR Fund
―
―
―
XLV
Health Care Select Sector SPDR Fund
―
―
―
VHT
Vanguard Health Care ETF
―
―
―
XBI
SPDR S&P BIOTECH ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents